P-0247 - Cetuximab as monotherapy in elderly patients with metastatic colorectal cancer

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Colon Cancer
Rectal Cancer
Presenter Esther Una Cidon
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors T. Hickish
  • Oncology Department, Royal Bournemouth Hospital NHS Foundation Trust, Bournemouth/UK



Cetuximab is a monoclonal antibody against epidermal growth factor receptor which is used in metastatic colorectal cancer treatment. Mostly used in combination with chemotherapy, sometimes it is used as monotherapy and given its favourable toxicity profile it could be a good choice for elderly patients.


We carried out a study to evaluate the safety and efficacy of this drug as monotherapy in an elderly population with metastatic colorectal cancer KRAS wild-type. The study evaluated only the first four months of treatment. Patients included were older than 74 and were seen once monthly with blood tests (routine haematology and a general biochemistry which included CEA) and a CT scan was done every two months.


We evaluated 31 patients (18 men and 13 women). Most common adverse reactions were acneiform rash (63%), hand-foot syndrome (11%), growth of eyelashes (12%), conjunctivitis (13%), paronychia (9.1%), hypomagnesemia (19%), stomatitis (17.5%) and gastrointestinal disorders (18%). Only in three cases it was necessary a reduction in the dose of the cetuximab (due to hepatic toxicity grade 3, diarrhoea grade 3 and stomatitis grade 3). Only four patients developed progressive disease while on the first four months, one of them within the first two months. 11 had stable disease and the rest had partial response.


The results demonstrated that cetuximab monotherapy is beneficial for the treatment of elderly patients with metastatic colorectal cancer and it has a favourable toxicity profile.